Literature DB >> 27325377

Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study.

Olena O Seminog1, Oyindamola I Ogunlaja1, David Yeates1, Michael J Goldacre2.   

Abstract

OBJECTIVE: Case reports suggest that there may be an increased risk of some cancers associated with sickle cell disease. However, population-based studies are scarce and there is no comprehensive enumeration of the risks across the whole range of site-specific cancers. Our aim was to provide this.
DESIGN: We used an English national dataset of linked statistical records of hospital admissions and deaths from 1999 to 2011 to undertake a retrospective cohort study.
SETTING: England. PARTICIPANTS: Records of all hospital admissions in England with SCD or with conditions included in the control cohort. MAIN OUTCOME MEASURES: Rate ratios were calculated comparing rates of cancer in a sickle cell disease cohort and a control cohort, confining the analyses to people whose ethnicity was recorded as Black.
RESULTS: Comparing the sickle cell disease cohort with the cohort without sickle cell disease, the rate ratio for all cancers combined was 2.1 (95% confidence interval 1.7-2.5). There were significantly high rate ratios for haematological malignancies, including Hodgkin's lymphoma (rate ratio 3.7, 1.5-8.4), non-Hodgkin's lymphoma (2.6, 1.3-4.8), multiple myeloma (5.5, 2.8-10.1), lymphoid leukaemia (3.3, 1.3-8.0) and myeloid leukaemia (10.0, 4.6-21.5). Four solid tumours showed elevated rate ratios: colon cancer (2.8, 1.2-5.5), non-melanoma skin cancer (4.4, 1.3-12.2), kidney cancer (5.4, 2.3-11.5) and thyroid cancer (5.1, 1.3-15.4).
CONCLUSIONS: The risk of some malignancies may be raised in patients with sickle cell disease. However, this study was based on administrative data without the scope to validate these against patients' full clinical records. Our findings need confirmation or refutation. If confirmed, work to elucidate, at the genetic and molecular level, why people with sickle cell disease have elevated risks of individual cancers might make contributions to the fundamental understanding of carcinogenesis. © The Royal Society of Medicine.

Entities:  

Keywords:  Sickle cell disease; cancer risk; epidemiology; haematological malignancies; record linkage studies

Mesh:

Year:  2016        PMID: 27325377      PMCID: PMC4976723          DOI: 10.1177/0141076816651037

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  25 in total

1.  Use of large medical databases to study associations between diseases.

Authors:  M Goldacre; L Kurina; D Yeates; V Seagroatt; L Gill
Journal:  QJM       Date:  2000-10

Review 2.  The role of cytokines in sickle cell disease.

Authors:  A C Makis; E C Hatzimichael; K L Bourantas
Journal:  Ann Hematol       Date:  2000-08       Impact factor: 3.673

Review 3.  Sickle cell anemia and hematological neoplasias.

Authors:  Semra Paydas
Journal:  Leuk Lymphoma       Date:  2002-07

4.  Transmission of chronic myeloid leukemia through peripheral-blood stem-cell transplantation.

Authors:  Frederic Baron; Marie-Françoise Dresse; Yves Beguin
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

Review 5.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

6.  Cancers and immune related diseases associated with Down's syndrome: a record linkage study.

Authors:  M J Goldacre; C J Wotton; V Seagroatt; D Yeates
Journal:  Arch Dis Child       Date:  2004-11       Impact factor: 3.791

7.  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Authors:  Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

8.  Renal medullary carcinoma and ABL gene amplification.

Authors:  Lijo Simpson; Xiang He; Michael Pins; Xiaoke Huang; Steven C Campbell; Ximing J Yang; Elizabeth J Perlman; Raymond C Bergan
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

9.  Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates.

Authors:  H Møller; S Richards; N Hanchett; S P Riaz; M Lüchtenborg; L Holmberg; D Robinson
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

10.  Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study.

Authors:  O O Seminog; M J Goldacre
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

View more
  18 in total

1.  Increased risk of leukemia among sickle cell disease patients in California.

Authors:  Ann Brunson; Theresa H M Keegan; Heejung Bang; Anjlee Mahajan; Susan Paulukonis; Ted Wun
Journal:  Blood       Date:  2017-08-22       Impact factor: 22.113

2.  Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.

Authors:  Jack Y Ghannam; Xin Xu; Irina Maric; Laura Dillon; Yuesheng Li; Matthew M Hsieh; Christopher S Hourigan; Courtney D Fitzhugh
Journal:  Blood       Date:  2020-04-02       Impact factor: 22.113

3.  Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.

Authors:  Matthew M Hsieh; Melissa Bonner; Francis John Pierciey; Naoya Uchida; James Rottman; Laura Demopoulos; Manfred Schmidt; Julie Kanter; Mark C Walters; Alexis A Thompson; Mohammed Asmal; John F Tisdale
Journal:  Blood Adv       Date:  2020-05-12

Review 4.  Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.

Authors:  Tolulope O Rosanwo; Daniel E Bauer
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

5.  Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.

Authors:  Sophie Ramadier; Anne Chalumeau; Tristan Felix; Nadia Othman; Sherazade Aknoun; Antonio Casini; Giulia Maule; Cecile Masson; Anne De Cian; Giacomo Frati; Megane Brusson; Jean-Paul Concordet; Marina Cavazzana; Anna Cereseto; Wassim El Nemer; Mario Amendola; Benoit Wattellier; Vasco Meneghini; Annarita Miccio
Journal:  Mol Ther       Date:  2021-08-19       Impact factor: 11.454

Review 6.  Clonal Hematopoiesis: From Mechanisms to Clinical Intervention.

Authors:  Thomas Köhnke; Ravindra Majeti
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

Review 7.  The transformative potential of HSC gene therapy as a genetic medicine.

Authors:  Pervinder Sagoo; H Bobby Gaspar
Journal:  Gene Ther       Date:  2021-05-26       Impact factor: 5.250

8.  Cancer specific survival in patients with sickle cell disease.

Authors:  Ann Brunson; Theresa H M Keegan; Anjlee Mahajan; Susan Paulukonis; Ted Wun
Journal:  Br J Haematol       Date:  2018-11-22       Impact factor: 6.998

9.  Clonal hematopoiesis in sickle cell disease.

Authors:  Thomas Pincez; Simon S K Lee; Yann Ilboudo; Michael Preuss; Anne-Laure Pham Hung d'Alexandry d'Orengiani; Pablo Bartolucci; Frédéric Galactéros; Philippe Joly; Daniel E Bauer; Ruth J F Loos; R Coleman Lindsley; Guillaume Lettre
Journal:  Blood       Date:  2021-11-25       Impact factor: 25.476

10.  Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S.

Authors:  Arianna Barbetta; Cameron Goldbeck; Angelina Lim; Sean P Martin; Jeffrey A Kahn; M Raashid Sheikh; Juliet Emamaullee
Journal:  HPB (Oxford)       Date:  2021-07-06       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.